NY-ESO-1 Assay Portfolio Service

Creative Biolabs has extensive experience in the field of immuno-oncology, our in-house experts specialize in the full spectrum of immuno oncology (IO) research and have the capability to provide comprehensive NY-ESO-1 assay portfolio services.

The Background of Tumor Target NY-ESO-1

NY-ESO-1 (New York esophageal squamous cell carcinoma 1), as a member of the cancer-testis antigen (CTA) family, is an 18-kDa protein with 180 amino acids presenting a glycine-rich N-terminal region and an extremely hydrophobic C-terminal region with a Pcc-1 domain.

NY-ESO-1 expression has been found in a variety range of tumor types, including metastatic melanoma, breast cancer, ovarian cancer, neuroblastoma, myeloma, bladder cancer, synovial sarcoma, esophageal cancer, hepatocellular cancer, head and neck cancer, non-small cell lung cancer and prostate cancer. Meanwhile, NY-ESO-1 expression could be considered as a prognostic biomarker, which expression is associated with poor clinical outcomes in some cancers.

NY-ESO-1 Targeted Therapeutics

NY-ESO-1 is widely considered to be a good candidate target for immunotherapy, because its restricted expression profile in healthy adult tissues effectively reduces the risk of off-target toxicity. To date, NY-ESO-1 targeted therapies have come a long way, targeting the antigen using a series of approaches from peptide and protein vaccinations, antibodies, adoptive T cell therapies to combinational treatment modalities. There have been some promising results, driving new clinical trials in many types of cancers.

NY-ESO-1 targeted approaches for cancer immunotherapy. Fig.1 NY-ESO-1 targeted approaches for cancer immunotherapy. (Thomas, 2018)

NY-ESO-1 Assay Portfolio Services

Creative Biolabs has robustly developed in vitro and in vivo platforms to provide reproducible NY-ESO-1 targeted assays for our clients all over the world. We are dedicated to designing comprehensive research practices and handling high-quality studies to support your biopharmaceutical development pipeline.

In vitro assays:

Tumor target validation
NY-ESO-1-targeted leads screening
Epitope mapping
Functional assay

In vivo assays:

Animal models for in vivo study of anti-NY-ESO-1 therapies
Toxicity evaluation
PK/PD study

For further details, please don't hesitate to contact us for more information.

Reference

Thomas, R.; et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Frontiers in immunology. 2018, 9:947.

For Research Use Only | Not For Clinical Use

Resources

Download our brochure

Online Inquiry